Department of Health Sciences, Section of Anaesthesiology, Intensive Care and Pain Medicine, University of Florence, Florence, Italy.
Department of Anaesthesia and Intensive Care, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Artif Organs. 2021 Nov;45(11):1300-1307. doi: 10.1111/aor.13991. Epub 2021 Aug 18.
Periodic dose assessment is quintessential for dynamic dose adjustment and quality control of continuous renal replacement therapy (CRRT) in critically ill patients with acute kidney injury (AKI). The flows-based methods to estimate dose are easy and reproducible methods to quantify (estimate) CRRT dose at the bedside. In particular, quantification of effluent flow and, mainly, the current dose (adjusted for dialysate, replacement, blood flows, and net ultrafiltration) is routinely used in clinical practice. Unfortunately, these methods are critically influenced by several external unpredictable factors; the estimated dose often overestimates the real biological delivered dose quantified through the measurement of urea clearance (the current effective delivered dose). Although the current effective delivered dose is undoubtedly more precise than the flows-based dose estimation in quantifying CRRT efficacy, some limitations are reported for the urea-based measurement of dose. This article aims to describe the standard of practice for dose quantification in critically ill patients with AKI undergoing CRRT in the intensive care unit. Pitfalls of current methods will be underlined, along with solutions potentially applicable to obtain more precise results in terms of (a) adequate marker solutes that should be used in accordance with the clinical scenario, (b) correct sampling procedures depending on the chosen indicator of transmembrane removal, (c) formulas for calculations, and (d) quality controls and benchmark indicators.
定期剂量评估对于危重病合并急性肾损伤(AKI)患者的连续性肾脏替代治疗(CRRT)的动态剂量调整和质量控制至关重要。基于流量的方法是一种简便且可重复的床边 CRRT 剂量量化(估计)方法。特别是,流出液流量的定量,主要是当前剂量(针对透析液、置换液、血流和净超滤进行调整),在临床实践中常规使用。不幸的是,这些方法受到许多外部不可预测因素的严重影响;估计的剂量通常会高估通过测量尿素清除率(当前有效的实际输送剂量)量化的真实生物输送剂量。尽管当前有效的实际输送剂量在量化 CRRT 疗效方面无疑比基于流量的剂量估计更精确,但据报道,基于尿素的剂量测量存在一些局限性。本文旨在描述 ICU 中接受 CRRT 的 AKI 危重病患者的剂量量化标准实践。将强调当前方法的缺陷,以及可能适用于获得更精确结果的解决方案,包括 (a) 应根据临床情况选择合适的标记溶质,(b) 根据所选跨膜清除指标选择正确的采样程序,(c) 计算公式,以及 (d) 质量控制和基准指标。